Specialist care lifts Ipsen's first half sales
This article was originally published in Scrip
Executive Summary
Ipsen's total drug sales rose by 6% to €503.9 million in the first half, buoyed by a 10% increase in specialist care sales. However, net profit fell by 11% to €98.7 million.